HIV-1 tropism and survival in vertically infected ugandan infants

Journal of Infectious Diseases

Volumn 197, Issue 10, 2008, Pages 1382-1388

  Church, Jessica D ^a   Huang, Wei ^b   Mwatha, Anthony ^c   Toma, Jonathan ^b   Stawiski, Eric ^b   Donnell, Deborah ^c   Guay, Laura A ^a   Mmiro, Francis ^a   Musoke, Philippa ^d   Jackson, J Brooks ^a   Parkin, Neil ^b   Eshleman, Susan H ^a,e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d MAKERERE UNIVERSITY   (Uganda)

^e DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; NEVIRAPINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; ENVELOPE GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; INFANT; NUCLEOTIDE SEQUENCE; PHYLOGENY; PLASMA; PRIORITY JOURNAL; PROPHYLAXIS; SEQUENCE ANALYSIS; SERUM; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; SURVIVAL RATE; UGANDA; VERTICAL TRANSMISSION; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS SURVIVAL;

CELL LINE; DISEASE TRANSMISSION, VERTICAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MOLECULAR SEQUENCE DATA; PHYLOGENY; PLASMA; RECEPTORS, HIV; SEQUENCE ANALYSIS, DNA; SERUM; SURVIVAL ANALYSIS; UGANDA;

EID: 43949103389     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/587492     Document Type: Article

References (36)

1. Coakley E, Petropoulos CJ, Whitcomb JM. Assessing chemokine coreceptor usage in HIV. Curr Opin Infect Dis 2005; 18:9-15.
2. van't Wout AB, Kootstra NA, Mulder-Kampinga GA, et al. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994; 94:2060-7.
3. Casper CH, Clevestig P, Carlenor E, et al. Link between the X4 phenotype in human immunodeficiency virus type 1-infected mothers and their children, despite the early presence of R5 in the child. J Infect Dis 2002; 186:914-21.
4. Zhang H, Orti G, Du Q, et al. Phylogenetic and phenotypic analysis of HIV type 1 env gp120 in cases of subtype C mother-to-child transmission. AIDS Res Hum Retroviruses 2002; 18:1415-23.
5. Matala E, Hahn T, Yedavalli VR, Ahmad N. Biological characterization of HIV type 1 envelope V3 regions from mothers and infants associated with perinatal transmission. AIDS Res Hum Retroviruses 2001; 17:1725-35.
6. Scarlatti G, Hodara V, Rossi P, et al. Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype. Virology 1993; 197:624-9.
7. Paul MO, Abrams EA, Pahwa S. Evidence for transmission of dualtropic HIV-1 from mother to child and reversion to macrophage tropism with age [abstract 232]? In: Program and abstracts of the 6th Conference on Retroviruses and Opportunisitic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1999.
8. Salvatori F, Scarlatti G. HIV type 1 chemokine receptor usage in mother-to-child transmission. AIDS Res Hum Retroviruses 2001; 17:925-35.
9. Fitzgibbon JE, Gaur S, Gavai M, Gregory P, Frenkel LD, John JF Jr. Effect of the HIV-1 syncytium-inducing phenotype on disease stage in vertically-infected children. J Med Virol 1998; 55:56-63.
10. Casper C, Naver L, Clevestig P, et al. Coreceptor change appears after immune deficiency is established in children infected with different HIV-1 subtypes. AIDS Res Hum Retroviruses 2002; 18:343-52.
11. Tscherning C, Alaeus A, Fredriksson R, et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 1998; 241:181-8.
12. Tscherning-Casper C, Vodros D, Menu E, et al. Coreceptor usage of HIV-1 isolates representing different genetic subtypes obtained from pregnant Cameroonian women. European Network for In Utero Transmission of HIV-1. J Acquir Immune Defic Syndr 2000; 24:1-9.
13. Huang W, Eshleman SH, Toma J, et al. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 2007; 81:7885-93.
14. Kaleebu P, Nankya IL, Yirrell DL, et al. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr 2007; 45:28-33.
15. Laeyendecker O, Li X, Arroyo M, et al. The effect of HIV subtype on rapid disease progression in Rakai, Uganda [abstract 44LB]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver). Alexandria, VA: Foundation for Retrovirology and Human Health, 2006.
16. Baeten JM, Chohan B, Lavreys L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007; 195:1177-80.
17. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
18. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 months follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362:859-68.
19. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51:566-75.
20. Kumar S, Tamura K, Nei M. MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform 2004; 5:150-63.
21. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992; 66:6777-80.
22. Fouchier RA, Groenink M, Kootstra NA, et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992; 66:3183-7.
23. Jensen MA, Li FS, van 't Wout AB, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003; 77:13376-88.
24. Jensen MA, Coetzer M, van 't Wout AB, Morris L, Mullins JI. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol 2006; 80:4698-704.
25. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15:1951-7.
26. Mofenson LM, Korelitz J, Meyer WA 3rd, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis 1997; 175:1029-38.
27. Dickover RE, Dillon M, Leung KM, et al. Early prognostic indicators in primary perinatal human immunodeficiency virus type 1 infection: importance of viral RNA and the timing of transmission on long-term outcome. J Infect Dis 1998; 178:375-87.
28. Rouet F, Sakarovitch C, Msellati P, et al. Pediatric viral human immunodeficiency virus type 1 RNA levels, timing of infection, and disease progression in African HIV-1-infected children. Pediatrics 2003; 112:e289.
29. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 1997; 336:1337-42.
30. Tuttle DL, Anders CB, Aquino-De Jesus MJ, et al. Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. AIDS Res Hum Retroviruses 2002; 18:353-62.
31. Eshleman SH, Guay LA, Fleming T, et al. Survival of Ugandan infants with subtype A and DHIV-1 infection (HIVNET 012). J Acquir Immune Defic Syndr 2002; 31:327-30.
32. Hartley O, Klasse PJ, Sattentau QJ, Moore JP. V3: HIV's switch-hitter. AIDS Res Hum Retroviruses 2005; 21:171-89.
33. Carrillo A, Ratner L. Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J Virol 1996; 70:1301-9.
34. Ghaffari G, Tuttle DL, Briggs D, et al. Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages. J Virol 2005; 79:13250-61.
35. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, Walker JM, Swanstrom R. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol 2002; 76:3852-64.
36. Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, Mosier DE. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 2006; 80:750-8.